Intensive care

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
11 Unique IMPs
0 Commercial trials
Drug classes (ATC)
B Haematology (ATC B) 2
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Heparin / LMWH 4 substances
Analgesic / antipyretic 1 substance
Supportive / diluent 1 substance
Phase IV: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase IV

2 trials
  • Centre Hospitalier Universitaire De Nantes Academic
    KETAMINE HYDROCHLORIDE; NEFOPAM HYDROCHLORIDE; PARACETAMOL; REMIFENTANIL HYDROCHLORIDE; SODIUM CHLORIDE; TRAMADOL HYDROCHLORIDE
    2024-517770-14-00 1 country 2025 n=50
    Ended
  • Rigshospitalet Academic
    DALTEPARIN SODIUM; ENOXAPARIN SODIUM; HUMAN PLASMA PROTEINS WITH NOT LESS THAN 96% ALBUMIN; NADROPARIN CALCIUM; TINZAPARIN SODIUM
    2024-516208-41-00 5 countries 2025 n=100,000
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Centre Hospitalier Universitaire De Nantes Academic 1 Phase IV 0
Rigshospitalet Academic 1 Phase IV 1
New trials by year
2025
2
← All indication landscapes